William L. Macias - Apr 25, 2023 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role: Chief Medical Officer
Signature: /s/ Eva Renee Barnett, attorney-in-fact for William L. Macias
Stock symbol: IMVT
Transactions as of: Apr 25, 2023
Transactions value $: -$8,292
Form type: 4
Date filed: 4/26/2023, 04:12 PM
Previous filing: Apr 14, 2023
Next filing: Jul 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMVT	Common Stock	Sale	-$8.29K	-509	-0.15%	$16.29	350K	Apr 25, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on April 13, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.11 - $16.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.

Content

On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,167 of these RSUs vested on April 13, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.11 - $16.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.